Target
5-hydroxytryptamine receptor 2B
Ligand
BDBM50086052
Substrate
n/a
Meas. Tech.
ChEMBL_2877 (CHEMBL617780)
Ki
25±n/a nM
Citation
 Bromidge, SMDabbs, SDavies, DTDavies, SDuckworth, DMForbes, ITGaster, LMHam, PJones, GEKing, FDMulholland, KRSaunders, DVWyman, PABlaney, FEClarke, SEBlackburn, TPHolland, VKennett, GALightowler, SMiddlemiss, DNTrail, BRiley, GJWood, MD Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem 43:1123-34 (2000) [PubMed]  Article 
Target
Name:
5-hydroxytryptamine receptor 2B
Synonyms:
5-HT-2B | 5-HT2B | 5-hydroxytryptamine (serotonin) receptor 2B [Homo sapiens] | 5-hydroxytryptamine receptor 2B (5-HT2B) | 5-hydroxytryptamine receptor 2C (5HT2C) | 5HT2B_HUMAN | HTR2B | Serotonin (5-HT3) receptor | Serotonin 2b (5-HT2b) receptor | Serotonin Receptor 2B
Type:
G Protein-Coupled Receptor (GPCR)
Mol. Mass.:
54312.47
Organism:
Homo sapiens (Human)
Description:
Receptor binding assays were performed using human clone stably expressed in CHO cells.
Residue:
481
Sequence:
MALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQGNKLHWAALLILMVIIPTIGGNTLVILAVSLEKKLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEAMWPLPLVLCPAWLFLDVLFSTASIMHLCAISVDRYIAIKKPIQANQYNSRATAFIKITVVWLISIGIAIPVPIKGIETDVDNPNNITCVLTKERFGDFMLFGSLAAFFTPLAIMIVTYFLTIHALQKKAYLVKNKPPQRLTWLTVSTVFQRDETPCSSPEKVAMLDGSRKDKALPNSGDETLMRRTSTIGKKSVQTISNEQRASKVLGIVFFLFLLMWCPFFITNITLVLCDSCNQTTLQMLLEIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNPMAENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTEEQVSYV
  
Inhibitor
Name:
BDBM50086052
Synonyms:
5-Methoxy-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid (4-chloro-3-pyridin-3-yl-phenyl)-amide | CHEMBL14469
Type:
Small organic molecule
Emp. Form.:
C22H17ClF3N3O2
Mol. Mass.:
447.837
SMILES:
COc1cc2CCN(C(=O)Nc3ccc(Cl)c(c3)-c3cccnc3)c2cc1C(F)(F)F
Structure:
Search PDB for entries with ligand similarity: